hydroxychloroquine has been researched along with Cardiotoxicity in 34 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The recent empirical use of hydroxychloroquine (HCQ) in coronavirus disease 2019 (COVID-19) revived the interest in its cardiac toxicity, increasingly sidelined over time." | 8.02 | Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic. ( Drici, MD; Fresse, A; Gérard, A; Micallef, J; Rocher, F; Romani, S; Van-Obberghen, É; Viard, D, 2021) |
| " Although, most adverse cardiac events related to HCQ/CQ usage in COVID-19 were secondary to conduction disorders given the short duration of treatment, HCQ/CQ can cause CM and HF, with chronic usage." | 6.82 | Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic. ( Gagnon, LR; Oudit, GY; Sadasivan, C; Yogasundaram, H, 2022) |
| " The goal of the present study was to evaluate the potential protective effect of the nootropic agent vinpocetine against CQ and HCQ adverse effects with a specific focus on the heart." | 5.91 | Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress. ( Abdelmageed, N; Ahmed, M; El-Banna, HA; El-Zorba, HY; Ghallab, A; Haridy, M; Hassan, R; Morad, OA; Morad, SAF; Seddek, AL; Twafik, WA, 2023) |
| "Hydroxychloroquine (HCQ) is a common antimalarial drug that has been used effectively in the treatment of various rheumatic and auto-immunity diseases." | 5.91 | Protective Effect of Quercetin and p-Coumaric Acid (p-CA) Against Cardiotoxicity: An ( Bhadana, R; Rani, V, 2023) |
| "In this case, cardiotoxicity is the consequence of the lysosomal dysfunction and the result of intracytoplasmic granular material inclusions." | 5.43 | [Early cardiotoxicity of Hydroxychloroquine]. ( Duhaut, P; Guillaumont, MP; Schmidt, J; Touati, G; Zerbib, Y, 2016) |
| "Forty-five ECGs were available for corrected QT interval (QTc) measurement, and levels of hydroxychloroquine were assessed during each trimester of pregnancy and in the cord blood, providing unambiguous assurance of drug exposure." | 5.34 | Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. ( Buyon, JP; Clancy, R; Cohen, R; Copel, J; Costedoat-Chalumeau, N; Cuneo, BF; Friedman, DM; Izmirly, PM; Kim, M; Masson, M; Phoon, CK; Saxena, A; Wainwright, BJ; Zahr, N, 2020) |
| "The recent empirical use of hydroxychloroquine (HCQ) in coronavirus disease 2019 (COVID-19) revived the interest in its cardiac toxicity, increasingly sidelined over time." | 4.02 | Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic. ( Drici, MD; Fresse, A; Gérard, A; Micallef, J; Rocher, F; Romani, S; Van-Obberghen, É; Viard, D, 2021) |
| " We report on a chronic preclinical drug screening platform, a cardiac microphysiological system (MPS), to assess cardiotoxicity associated with repurposed hydroxychloroquine (HCQ) and azithromycin (AZM) polytherapy in a mock phase I safety clinical trial." | 4.02 | In vitro safety "clinical trial" of the cardiac liability of drug polytherapy. ( Charrez, B; Charwat, V; Edwards, AG; Finsberg, H; Healy, KE; Miller, EW; Siemons, B, 2021) |
| "A 59-year-old man with a history of ischemic-labeled heart disease revealed by conduction disorders and cutaneous lupus treated initially with hydroxychloroquine followed by chloroquine consulted for asthenia and weight loss." | 3.96 | [A rare cause of impaired general condition: Muscular and cardiac toxicity of antimalarials]. ( Costedoat-Chalumeau, N; Dion, J; Lenfant, T; Maisonobe, T, 2020) |
| "The risk of torsade de pointes is low in hospitalized patients with COVID-19 receiving hydroxychloroquine±azithromycin therapy." | 3.96 | Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era. ( Chang, D; Epstein, LM; Fishbein, J; Gabriels, J; Mountantonakis, SE; Qiu, M; Saleh, M, 2020) |
| " Although, most adverse cardiac events related to HCQ/CQ usage in COVID-19 were secondary to conduction disorders given the short duration of treatment, HCQ/CQ can cause CM and HF, with chronic usage." | 2.82 | Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic. ( Gagnon, LR; Oudit, GY; Sadasivan, C; Yogasundaram, H, 2022) |
| " The meta-analysis indicated that the risk of adverse effects (AEs) in the HCQ group was significantly increased compared with that in the control group (RD 0." | 2.72 | Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials. ( Chen, C; Chen, Z; Li, X; Lv, Q; Pan, K; Wu, B; Xu, Q, 2021) |
| " However, some of these medications have potential cardiac adverse effects." | 2.66 | Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. ( Lazar, S; Naksuk, N; Peeraphatdit, TB, 2020) |
| " The goal of the present study was to evaluate the potential protective effect of the nootropic agent vinpocetine against CQ and HCQ adverse effects with a specific focus on the heart." | 1.91 | Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress. ( Abdelmageed, N; Ahmed, M; El-Banna, HA; El-Zorba, HY; Ghallab, A; Haridy, M; Hassan, R; Morad, OA; Morad, SAF; Seddek, AL; Twafik, WA, 2023) |
| "Hydroxychloroquine (HCQ) is a common antimalarial drug that has been used effectively in the treatment of various rheumatic and auto-immunity diseases." | 1.91 | Protective Effect of Quercetin and p-Coumaric Acid (p-CA) Against Cardiotoxicity: An ( Bhadana, R; Rani, V, 2023) |
| " Awareness of the potential adverse cardiac effects of HCQ and CQ can increase the safe use of these medications." | 1.62 | American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. ( Costenbader, KH; Desmarais, J; Fett, N; Ginzler, EM; Goodman, S; Kovacs, R; Link, MS; O'Dell, J; Pineau, CA; Rosenbaum, JT; Schmajuk, G; Werth, VP, 2021) |
| "In this case, cardiotoxicity is the consequence of the lysosomal dysfunction and the result of intracytoplasmic granular material inclusions." | 1.43 | [Early cardiotoxicity of Hydroxychloroquine]. ( Duhaut, P; Guillaumont, MP; Schmidt, J; Touati, G; Zerbib, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (14.71) | 24.3611 |
| 2020's | 29 (85.29) | 2.80 |
| Authors | Studies |
|---|---|
| Yendrapalli, U | 1 |
| Ali, H | 1 |
| Green, JL | 1 |
| Edwards, J | 1 |
| Desmarais, J | 1 |
| Rosenbaum, JT | 1 |
| Costenbader, KH | 1 |
| Ginzler, EM | 1 |
| Fett, N | 1 |
| Goodman, S | 1 |
| O'Dell, J | 1 |
| Pineau, CA | 1 |
| Schmajuk, G | 1 |
| Werth, VP | 1 |
| Link, MS | 1 |
| Kovacs, R | 1 |
| Gagnon, LR | 1 |
| Sadasivan, C | 1 |
| Yogasundaram, H | 1 |
| Oudit, GY | 1 |
| Seydi, E | 1 |
| Hassani, MK | 1 |
| Naderpour, S | 1 |
| Arjmand, A | 1 |
| Pourahmad, J | 1 |
| Abdelmageed, N | 1 |
| Twafik, WA | 1 |
| Morad, OA | 1 |
| Haridy, M | 1 |
| Hassan, R | 1 |
| Ahmed, M | 1 |
| El-Zorba, HY | 1 |
| El-Banna, HA | 1 |
| Seddek, AL | 1 |
| Ghallab, A | 1 |
| Morad, SAF | 1 |
| Alsmadi, MM | 1 |
| Jaradat, MM | 1 |
| Obaidat, RM | 1 |
| Alnaief, M | 1 |
| Tayyem, R | 1 |
| Idkaidek, N | 1 |
| Bhadana, R | 1 |
| Rani, V | 1 |
| Hanneman, K | 1 |
| Alberdi, HV | 1 |
| Karur, GR | 1 |
| Tselios, K | 1 |
| Harvey, PJ | 1 |
| Gladman, DD | 1 |
| Akhtari, S | 1 |
| Osuntokun, T | 1 |
| Wald, RM | 1 |
| Thavendiranathan, P | 1 |
| Butany, J | 1 |
| Urowitz, MB | 1 |
| Bauman, JL | 1 |
| Tisdale, JE | 1 |
| Lentini, G | 1 |
| Cavalluzzi, MM | 1 |
| Habtemariam, S | 1 |
| Lenfant, T | 1 |
| Dion, J | 1 |
| Maisonobe, T | 1 |
| Costedoat-Chalumeau, N | 2 |
| Becker, RC | 1 |
| Monzani, A | 1 |
| Genoni, G | 1 |
| Scopinaro, A | 1 |
| Pistis, G | 1 |
| Kozel, D | 1 |
| Secco, GG | 1 |
| Naksuk, N | 1 |
| Lazar, S | 1 |
| Peeraphatdit, TB | 1 |
| Khalaf, S | 1 |
| Khan, N | 1 |
| Al-Mallah, M | 1 |
| Kassi, M | 1 |
| Shah, D | 1 |
| Nguyen, LS | 1 |
| Dolladille, C | 1 |
| Drici, MD | 2 |
| Fenioux, C | 1 |
| Alexandre, J | 1 |
| Mira, JP | 1 |
| Moslehi, JJ | 1 |
| Roden, DM | 1 |
| Funck-Brentano, C | 1 |
| Salem, JE | 1 |
| Kamp, TJ | 1 |
| Hamdan, MH | 1 |
| January, CT | 1 |
| Simmering, JE | 1 |
| Polgreen, LA | 1 |
| Polgreen, PM | 1 |
| Teske, RE | 1 |
| Comellas, AP | 1 |
| Carter, BL | 1 |
| Chen, C | 1 |
| Pan, K | 1 |
| Wu, B | 1 |
| Li, X | 2 |
| Chen, Z | 1 |
| Xu, Q | 1 |
| Lv, Q | 1 |
| Friedman, DM | 1 |
| Kim, M | 1 |
| Clancy, R | 1 |
| Copel, J | 1 |
| Phoon, CK | 1 |
| Cuneo, BF | 1 |
| Cohen, R | 1 |
| Masson, M | 1 |
| Wainwright, BJ | 1 |
| Zahr, N | 1 |
| Saxena, A | 1 |
| Izmirly, PM | 1 |
| Buyon, JP | 1 |
| Hummel, JP | 1 |
| Maraj, I | 1 |
| Taoutel, R | 1 |
| Chamoun, R | 1 |
| Workman, VK | 1 |
| Tran, L | 1 |
| Abboud, JM | 1 |
| Afif, C | 1 |
| Chouairi, S | 1 |
| Delvecchio, A | 1 |
| Howes, CJ | 1 |
| Enriquez, AD | 1 |
| Akar, JG | 1 |
| Romani, S | 1 |
| Gérard, A | 1 |
| Fresse, A | 1 |
| Viard, D | 1 |
| Van-Obberghen, É | 1 |
| Micallef, J | 1 |
| Rocher, F | 1 |
| Saleh, M | 1 |
| Gabriels, J | 1 |
| Chang, D | 1 |
| Fishbein, J | 1 |
| Qiu, M | 1 |
| Mountantonakis, SE | 1 |
| Epstein, LM | 1 |
| Bansal, P | 1 |
| Goyal, A | 1 |
| Cusick, A | 1 |
| Lahan, S | 1 |
| Dhaliwal, HS | 1 |
| Bhyan, P | 1 |
| Bhattad, PB | 1 |
| Aslam, F | 1 |
| Ranka, S | 1 |
| Dalia, T | 1 |
| Chhabra, L | 1 |
| Sanghavi, D | 1 |
| Sonani, B | 1 |
| Davis, JM | 1 |
| Paul, M | 1 |
| Pothen, L | 1 |
| Yildiz, H | 1 |
| Samnick, MM | 1 |
| Yombi, JC | 1 |
| Egeli, BH | 1 |
| Sparks, JA | 1 |
| Kim, AHJ | 1 |
| Liew, JW | 1 |
| Jordaan, P | 1 |
| Dumotier, B | 1 |
| Traebert, M | 1 |
| Miller, PE | 1 |
| Ghetti, A | 1 |
| Urban, L | 1 |
| Abi-Gerges, N | 1 |
| Charrez, B | 1 |
| Charwat, V | 1 |
| Siemons, B | 1 |
| Finsberg, H | 1 |
| Miller, EW | 1 |
| Edwards, AG | 1 |
| Healy, KE | 1 |
| Chang, ICY | 1 |
| Bois, JP | 1 |
| Bois, MC | 1 |
| Maleszewski, JJ | 1 |
| Johnson, GB | 1 |
| Grogan, M | 1 |
| Dogar, MU | 1 |
| Shah, NN | 1 |
| Ishtiaq, S | 1 |
| Shah, PN | 1 |
| Shah, P | 1 |
| Mathew, S | 1 |
| Vittorio, TJ | 1 |
| Chatre, C | 1 |
| Roubille, F | 1 |
| Vernhet, H | 1 |
| Jorgensen, C | 1 |
| Pers, YM | 1 |
| Cairoli, E | 1 |
| Danese, N | 1 |
| Teliz, M | 1 |
| Bruzzone, MJ | 1 |
| Ferreira, J | 1 |
| Rebella, M | 1 |
| Cayota, A | 1 |
| Zerbib, Y | 1 |
| Guillaumont, MP | 1 |
| Touati, G | 1 |
| Duhaut, P | 1 |
| Schmidt, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preventive Approach to Congenital Heart Block With Hydroxychloroquine[NCT01379573] | Phase 2 | 74 participants (Actual) | Interventional | 2011-01-01 | Completed | ||
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01379573)
Timeframe: At birth (approximately 9 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
a) shortening fraction <28% = 2 SD below normal mean or qualitatively reduced systolic function; b) cardio-thoracic ratio >0.33; c) hydropic changes; d) moderate/severe tricuspid regurgitation. (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
(NCT01379573)
Timeframe: At birth (approximately 9 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 1 |
(NCT01379573)
Timeframe: Up to 15 months (at birth - 9 months, and 6 months thereafter)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 4 |
(see title) (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
"An autopsy with full evaluation of the heart will be encouraged but cannot be mandated. If AV block or evidence of a cardiomyopathy can be proven, then these will provide the basis for final categorization. If not possible, the death will not be considered a recurrence rate but will be reported." (NCT01379573)
Timeframe: Up to 9 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
(gestational age <37 weeks at birth) (NCT01379573)
Timeframe: At birth (approximately 9 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 9 |
EKG at birth must confirm 1st degree AV block. It is also possible that a fetus developing 1st degree block on study medication might have developed more advanced block in the absence of study medication. (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
Echocardiogram reveals 2nd or 3rd degree AV block (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 5 |
8 reviews available for hydroxychloroquine and Cardiotoxicity
| Article | Year |
|---|---|
Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.
Topics: Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Heart Failure; Humans; Hydroxychloroquine; Pan | 2022 |
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antimalarials; Arrhythmias, Cardiac; Betacoronavirus; | 2020 |
Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
Topics: Betacoronavirus; Cardiotoxicity; Chloroquine; Coronavirus Infections; COVID-19; Global Health; Heart | 2020 |
Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.
Topics: Cardiotoxicity; COVID-19 Drug Treatment; Gastrointestinal Tract; Humans; Hydroxychloroquine; Outcome | 2021 |
Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019.
Topics: Antimalarials; Cardiotoxicity; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 | 2021 |
Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?
Topics: Antiviral Agents; Autoimmune Diseases; Cardiotoxicity; COVID-19 Drug Treatment; Humans; Hydroxychlor | 2021 |
Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?
Topics: Antiviral Agents; Cardiotoxicity; Coronavirus Infections; COVID-19 Drug Treatment; Humans; Hydroxych | 2021 |
Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.
Topics: Antimalarials; Cardiotoxicity; Chloroquine; Dose-Response Relationship, Drug; Female; Heart Diseases | 2018 |
1 trial available for hydroxychloroquine and Cardiotoxicity
| Article | Year |
|---|---|
Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation.
Topics: Antiviral Agents; Cardiotoxicity; Drug Administration Schedule; Drug Monitoring; Electrocardiography | 2020 |
25 other studies available for hydroxychloroquine and Cardiotoxicity
| Article | Year |
|---|---|
Effects of cardiac toxicity of combination therapy with hydroxychloroquine and azithromycin in COVID-19 patients.
Topics: Azithromycin; Cardiotoxicity; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Retrospective Stu | 2021 |
American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.
Topics: Antimalarials; Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine | 2021 |
Cardiotoxicity of chloroquine and hydroxychloroquine through mitochondrial pathway.
Topics: Cardiotoxicity; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochromes c; Humans; Hydroxychloro | 2023 |
Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress.
Topics: Animals; Cardiotoxicity; Chloroquine; COVID-19; COVID-19 Drug Treatment; Hydroxychloroquine; Mice; O | 2023 |
The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel.
Topics: Animals; Cardiotoxicity; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lung; Rats | 2023 |
Protective Effect of Quercetin and p-Coumaric Acid (p-CA) Against Cardiotoxicity: An
Topics: Cardiotoxicity; Humans; Hydroxychloroquine; Molecular Docking Simulation; Quercetin | 2023 |
Antimalarial-Induced Cardiomyopathy Resembles Fabry Disease on Cardiac MRI.
Topics: Adult; Aged; Antimalarials; Biopsy; Cardiomyopathies; Cardiotoxicity; Chloroquine; Diagnosis, Differ | 2020 |
Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity.
Topics: Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Risk Factors; SARS | 2020 |
COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
Topics: Antimalarials; Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Cardiotoxicity; Chloroquine; | 2020 |
[A rare cause of impaired general condition: Muscular and cardiac toxicity of antimalarials].
Topics: Antimalarials; Asthenia; Biopsy; Cardiotoxicity; Diagnosis, Differential; Humans; Hydroxychloroquine | 2020 |
Covid-19 treatment update: follow the scientific evidence.
Topics: Animals; Antiviral Agents; Betacoronavirus; Cardiotoxicity; Cardiovascular Diseases; Clinical Trials | 2020 |
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Chloroquine; Coronavirus Infec | 2020 |
A positive PYP scan: Thinking beyond amyloid.
Topics: Antirheumatic Agents; Cardiomyopathies; Cardiotoxicity; Female; Humans; Hydroxychloroquine; Lupus Er | 2021 |
Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database.
Topics: Azithromycin; Cardiotoxicity; COVID-19; COVID-19 Drug Treatment; Databases, Factual; Electrocardiogr | 2020 |
The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Azithromycin; Cardiotoxicity; Cardiovascula | 2020 |
Temporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection.
Topics: Action Potentials; Aged; Antiviral Agents; Arrhythmias, Cardiac; Cardiotoxicity; Coronavirus Infecti | 2020 |
Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic.
Topics: Adult; Aged; Cardiomyopathies; Cardiotoxicity; COVID-19 Drug Treatment; Female; Heart Conduction Sys | 2021 |
Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.
Topics: Action Potentials; Adolescent; Adult; Aged; Antiviral Agents; Azithromycin; Cardiotoxicity; COVID-19 | 2020 |
Has the door closed on hydroxychloroquine for SARS-COV-2?
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; COVID-19 Drug Treatment; Drug | 2021 |
Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Cardiotoxicity; Chloroquine; COVID-1 | 2021 |
In vitro safety "clinical trial" of the cardiac liability of drug polytherapy.
Topics: Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Clinical Trials as Topic; COVID-19 Drug Treatmen | 2021 |
Hydroxychloroquine-Mediated Cardiotoxicity With a False-Positive
Topics: Aged; Amyloidosis; Antirheumatic Agents; Cardiotoxicity; Echocardiography; Female; Humans; Hydroxych | 2018 |
Hydroxychloroquine-induced restrictive cardiomyopathy: a case report.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Cardiomyopathies; Cardiotoxicity; Disease Progr | 2018 |
Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Cardiotoxicity; Dose-Response Relationship, D | 2015 |
[Early cardiotoxicity of Hydroxychloroquine].
Topics: Aged; Antimalarials; Cardiotoxicity; Endocarditis, Bacterial; Female; Humans; Hydroxychloroquine; Wh | 2016 |